Trump Slams DOJ for 'Slow-Walking' Marijuana Rescheduling in 2026

Four months after President Donald Trump signed an executive order directing the attorney general to complete marijuana rescheduling "in the most expeditious manner," the federal review has barely moved. On April 20, 2026, Trump himself publicly complained that the Department of Justice is "slow-walking" the reform — an extraordinary rebuke from a president to his own agency, and a signal that the long-awaited shift of cannabis from Schedule I to Schedule III is still anything but guaranteed.

The frustration lands in the middle of 4/20 week, the cultural high point of the cannabis calendar, when operators, patients, and reform advocates had expected tangible progress. Instead, the DEA's rescheduling appeal process remains paused, a newly filed DOJ status report confirms the review is "pending," and cannabis stocks that rallied on rescheduling optimism continue to trade on sentiment rather than substance.

What Trump Said and Why It Matters

In remarks and a social media post on April 20, Trump voiced dissatisfaction that the rescheduling process has not produced a decision more than 120 days after his executive directive. He framed the delay as bureaucratic foot-dragging and pushed senior DOJ officials to act. Marijuana Moment reported that Trump specifically accused the department of "slow-walking" the reform — language typically reserved for the kind of internal opposition he views as political.

For cannabis reform, the rhetoric matters because the mechanics of rescheduling flow through the DOJ and the DEA. The executive order was unusual in its specificity: it told the attorney general to complete the reform "expeditiously." A normal rescheduling under the Controlled Substances Act is a slow, evidence-driven administrative process — one that can take years. Trump's order compressed the political clock, but the agencies responsible for executing it did not compress the legal clock.

The State of the Appeal Process

The DEA filed a notice indicating the rescheduling proceeding "remains pending." Administrative law judges had previously set a hearing calendar, but that calendar has been paused while the agency reviews its path forward. Industry attorneys describe the current posture as a holding pattern: the DEA will not move without political and legal cover, and the DOJ has not yet supplied that cover in writing.

Several factors explain the caution. Intervenors aligned with prohibitionist groups have challenged both the evidence supporting rescheduling and the standing of the review process itself. The DEA's own internal skeptics — long resistant to moving cannabis out of Schedule I — have reportedly slowed internal concurrence on draft findings. And the administration's parallel move on psychedelics, announced the same weekend, has drawn attention and legal resources away from the marijuana file.

Why Schedule III Still Matters to the Industry

Whether the rescheduling arrives in 2026 or slides into 2027, the financial stakes for licensed cannabis operators are enormous. The single biggest prize is Internal Revenue Code Section 280E, which currently bars state-legal cannabis businesses from deducting ordinary business expenses. Moving marijuana to Schedule III would end the 280E penalty and, according to MJBizDaily analysts, could free up more than a billion dollars in after-tax cash flow across public multistate operators alone.

Rescheduling would also open doors that have been locked since the start of the legal industry: expanded access to FDIC-insured banking relationships, wider acceptance from major insurers, a cleaner path for institutional capital, and fewer roadblocks for clinical research. It would not, by itself, legalize recreational cannabis at the federal level — that would still require Congress — but it would materially reshape the economics of an industry that, per Flowhub's 2026 statistics, is on pace for nearly $47 billion in U.S. sales this year.

The Political Calculus Heading Into Summer

Trump's public pressure is designed to force the DOJ's hand, but legal observers caution that presidential frustration does not by itself accelerate administrative review. What could move the needle is a written directive from the attorney general, a formal brief from the Office of Legal Counsel endorsing the Schedule III pathway, or a DEA decision to reopen the hearing calendar with a compressed timeline.

Congress is moving on parallel tracks that could matter. The bipartisan STATES 2.0 Act, introduced earlier this year, would end the federal prohibition of cannabis and leave drug policy to the states. The bill was referred to the House Committee on Energy and Commerce in April. Separately, a congressional committee is preparing a directive requiring federal agencies to formally study the "adequacy" of state marijuana laws — a process that could either support rescheduling or become another delay vector.

What This Means for Consumers, Patients, and Operators

For the 54 million Americans who live in adult-use legal states and the millions more with medical cards, rescheduling changes almost nothing about day-to-day access. State-regulated markets will continue to operate under state law, dispensaries will remain cash-heavy, and products on shelves will not change.

For operators, the wait is more costly by the month. Every quarter of delay is another quarter of punitive taxation under 280E and another quarter of capital markets that refuse to price cannabis as a normal consumer-packaged-goods category. For patients — especially those using cannabis for chronic pain, PTSD, or cancer-related symptoms — Schedule III would formally recognize medical value, potentially unlocking more clinical trials and eventually a broader evidence base.

The April 20 frustration from the White House doesn't resolve the question. But it does make clear that the administration wants movement, and that the inertia inside the DEA and DOJ is the final barrier.

Key Takeaways

• President Trump accused the DOJ of "slow-walking" marijuana rescheduling on April 20, 2026, four months after his executive order.
• The DEA appeal process remains paused, with the agency stating the matter is "pending."
• Schedule III would end the 280E tax penalty — the single largest financial prize for licensed cannabis operators.
• Congress is advancing parallel efforts including the bipartisan STATES 2.0 Act.
• State-legal markets continue operating unchanged while federal reform drags on.

Explore cannabis news, find dispensaries, and join the community at Budpedia.